A method for purifying bortezomib
By using pH difference and extraction technology, combined with recrystallization step, the problem of difficulty in removing impurities and optical isomers during bortezomib synthesis is solved, and efficient purification and industrial production of high-purity bortezomib are achieved.
Patent Information
- Application Number
- CN202411247785.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-06
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-09-06
AI Technical Summary
Bortezomib is easily oxidized and degraded during the synthesis process, resulting in impurities and the configuration of chiral carbon is easily flipped, making it difficult to remove optical isomers and is difficult to effectively purify the prior art.
By utilizing the pH difference between impurities and bortezomib, high purity purification of bortezomib is achieved by using the steps of ethyl acetate and water system extraction, alkali aqueous solution washing and saturated brine washing, etc., combined with recrystallization.
The production of high-purity bortezomib is achieved, with a simple and efficient process, reducing energy consumption and three wastes, reducing production costs, and suitable for industrial production.
Smart Images

Figure CN118754928B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of drug purification, and in particular to a method for purifying bortezomib. Background Art
[0002] Bortezomib is a dipeptidyl boronate analogue and the world's first artificially synthesized new proteasome inhibitor for clinical use. In the synthesis route of bortezomib, the carbon-boron bond is easily oxidized and degraded, generating a large number of impurities that are difficult to remove; the chiral configuration of the chiral carbon of phenylalanine is easily flipped, resulting in optical isomers of the raw material drug that are difficult to remove. The main reason is that the product itself and the intermediate are unstable.
[0003] The bortezomib reaction solution obtained under the micro-chemical production process has many impurities and a complex structure. After analysis, the purpose of purification is achieved by utilizing the difference in pH between the impurities and bortezomib.
[0004] The above contents are only used to assist in understanding the technical solution of the present invention and do not constitute an admission that the above contents are prior art. Summary of the invention
[0005] The main purpose of the present invention is to provide a method for purifying bortezomib by utilizing the difference in pH between impurities and bortezomib.
[0006] Purification principle: The initially obtained bortezomib reaction solution is weakly acidic, and the alkaline impurities exist in the form of sulfates, while bortezomib exists in a free form. The alkaline impurities can be removed by extraction with ethyl acetate and water system. The acidic impurities have different acidities from bortezomib, and most of the acidic impurities can be removed by washing with a suitable alkaline aqueous solution.
[0007] To achieve the above object, the present invention provides a method for purifying bortezomib, comprising the following steps:
[0008] Dissolve the crude bortezomib in water, adjust the pH value to 5-7, extract with ethyl acetate three times, combine the organic phases, wash with water, alkaline water, and saturated brine, and dry and concentrate to obtain pure bortezomib;
[0009] The purified bortezomib is dissolved in an organic solvent and recrystallized twice to obtain high-purity bortezomib.
[0010] Wherein, the organic solvent is selected from one or more of ethyl acetate, n-heptane, toluene, acetone, acetonitrile, methyl tert-butyl ether, tetrahydrofuran, methanol, ethanol and dichloromethane;
[0011] The alkaline substance in the alkaline water washing is selected from one or more of sodium carbonate, sodium bicarbonate, potassium carbonate, sodium hydroxide, potassium hydroxide and lithium hydroxide.
[0012] The above-mentioned crude bortezomib is a product synthesized by micro-chemical production process.
[0013] The present invention has achieved the following beneficial effects:
[0014] High-purity products can be obtained through extraction and recrystallization. The whole process is simple and efficient, reduces energy consumption and three wastes, is green and environmentally friendly, reduces production costs, and can be used for industrial production. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] Figure 1 1 is a high performance liquid phase diagram of bortezomib before purification according to an embodiment of the present invention.
[0016] Figure 2 It is a high performance liquid phase diagram of the purified bortezomib involved in the embodiment of the present invention.
[0017] The realization of the purpose, functional features and advantages of the present invention will be further explained in conjunction with embodiments and with reference to the accompanying drawings. DETAILED DESCRIPTION
[0018] In order to make the purpose, technical solution and advantages of the embodiments of the present disclosure clearer, the technical solution of the embodiments of the present disclosure will be clearly and completely described below in conjunction with the drawings of the embodiments of the present disclosure. Obviously, the described embodiments are part of the embodiments of the present disclosure, rather than all of the embodiments. Based on the described embodiments of the present disclosure, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present disclosure.
[0019] The present invention provides a method for purifying bortezomib, which is applied to purifying a crude bortezomib synthesized by a micro-chemical production process, and comprises the following steps:
[0020] Dissolve the crude bortezomib in water, adjust the pH value to 5-7, extract with ethyl acetate three times, combine the organic phases, wash with water, alkaline water, and saturated brine, and dry and concentrate to obtain pure bortezomib;
[0021] The purified bortezomib is dissolved in an organic solvent and recrystallized twice to obtain high-purity bortezomib.
[0022] Wherein, the organic solvent is selected from one or more of ethyl acetate, n-heptane, toluene, acetone, acetonitrile, methyl tert-butyl ether, tetrahydrofuran, methanol, ethanol and dichloromethane;
[0023] The alkaline substance in the alkaline water washing is selected from one or more of sodium carbonate, sodium bicarbonate, potassium carbonate, sodium hydroxide, potassium hydroxide and lithium hydroxide.
[0024] Microchemical production process
[0025] Prepare reaction solution A: weigh 86 g of raw material A 100 g raw material B and 102 gTBTU ( ) was dissolved in organic solvent DMF (N,N-dimethylformamide) and the volume was made up to 1000 mL.
[0026] Prepare reaction solution B: weigh 80 g of triethylamine, dissolve it in organic solvent DMF (N,N-dimethylformamide), and make up to 1000 mL.
[0027] Prepare reaction solution C: weigh 32 g of methylboric acid, dissolve it in 300 mL of 1 M dilute sulfuric acid, and dilute to 1000 mL with organic solvent DMF (N,N-dimethylformamide).
[0028] n-heptane was used directly as reaction liquid D.
[0029] The reaction liquid A and the reaction liquid B are respectively transported to the micro mixer I at a set flow rate for mixing, and the mixed materials are transported to the tubular reactor I for the first step reaction to obtain the first step reaction liquid;
[0030] Reaction liquid C and reaction liquid D are respectively transported to the micro mixer II with the first step reaction liquid at a set flow rate for mixing, and the mixed materials are transported to the tubular reactor II for the second step reaction to obtain the second step reaction liquid;
[0031] The flow rates of reaction liquid A, reaction liquid B, reaction liquid C and reaction liquid D were all 2.5 mL / min; the reaction temperatures were all room temperature; the residence time of tubular reactor I in the first step reaction was 10 min, and the residence time of tubular reactor II in the second step reaction was 20 min.
[0032] For the specific process parameters of the microchemical production process for synthesizing bortezomib, please refer to the Chinese invention patent (CN117820347 A).
[0033] Purification methods
[0034] Dissolve the crude bortezomib in water, adjust the pH value to 5-7, extract with ethyl acetate three times, combine the organic phases, wash with water, alkaline water, and saturated brine, and dry and concentrate to obtain pure bortezomib;
[0035] The purified bortezomib is dissolved in an organic solvent and recrystallized twice to obtain high-purity bortezomib.
[0036] Wherein, the organic solvent is selected from one or more of ethyl acetate, n-heptane, toluene, acetone, acetonitrile, methyl tert-butyl ether, tetrahydrofuran, methanol, ethanol and dichloromethane;
[0037] The alkaline substance in the alkaline water washing is selected from one or more of sodium carbonate, sodium bicarbonate, potassium carbonate, sodium hydroxide, potassium hydroxide and lithium hydroxide.
[0038] Purity analysis method
[0039] Bortezomib was analyzed by high performance liquid chromatography using octadecylsilane bonded silica gel as the filling column (Aglient Poroshell 120 C18, 4.6 100mm, 2.7um), acetonitrile as mobile phase A, 0.02M ammonium acetate (1.0g acetic acid) as mobile phase B, and gradient elution was performed according to the following procedure.
[0040]
[0041] Among them, the detection wavelength was 254nm and the column temperature was controlled at 35℃.
[0042] Example 1
[0043] The reaction solution (4 L) containing bortezomib was allowed to stand for stratification, diluted with water (10 L), the pH value was adjusted to 5.9, extracted three times with ethyl acetate (3 L × 3), the organic phases (about 10 L) were combined, washed once with 3 L of pure water, once with 3 L of saturated sodium bicarbonate solution, once with 3 L of saturated brine, dried with 1 kg of anhydrous sodium sulfate for 18 h, filtered, and concentrated to obtain light yellow bortezomib (about 150 g);
[0044] Dissolve light yellow bortezomib (about 150 g) in acetone (1 L), heat until completely dissolved, then slowly cool to 0°C, let stand for 18 h, precipitate solid, filter to obtain white bortezomib (about 120 g), then dissolve white bortezomib (about 120 g) in acetonitrile (900 mL), heat to 60°C, wait until the solid is completely dissolved, then slowly cool to 0°C, let stand for 18 h, precipitate solid, filter, and dry in a vacuum drying oven (35°C) for 3 h to obtain white bortezomib (about 91.1 g), with a liquid phase purity of 99.87%, and a two-step total yield of 90.0% (see Figure 1 and Figure 2 ).
[0045] Embodiment 2-9
[0046] The difference from Example 1 is that the alkaline substance in the alkaline water washing is different, and other conditions are the same.
[0047]
[0048] Note: HOBt is 1-hydroxybenzotriazole.
[0049] Examples 10-17
[0050] The difference from Example 1 is the organic solvent, and other conditions are the same.
[0051]
[0052] Note: A / B in the organic solvent means that A is the organic solvent in the first recrystallization process, and B is the organic solvent in the second recrystallization process.
[0053] Examples 18-23
[0054] The difference from Example 1 is the pH value, and other conditions are the same.
[0055]
Claims
1. A method for purifying bortezomib, It is characterized in that The following steps are involved: The crude bortezomib was dissolved in water, the pH value was adjusted to 5.9, and the mixture was extracted with ethyl acetate three times. The organic phases were combined, washed with water, saturated sodium bicarbonate, and saturated brine, and dried and concentrated to obtain pure bortezomib. The pure bortezomib was dissolved in acetone, heated until completely dissolved, then slowly cooled to 0°C, allowed to stand for 18 hours, solid matter was precipitated, and then the solid matter was dissolved in acetonitrile, heated to 60°C, and allowed to stand for 18 hours until the solid matter was completely dissolved, then slowly cooled to 0°C, allowed to stand for 18 hours, to obtain high-purity bortezomib.
2. The method according to claim 1, It is characterized in that The crude bortezomib product is synthesized by the following process: Prepare reaction solution A: Raw material A 、Raw material B and TBTU were dissolved in the organic solvent DMF; Prepare reaction solution B: dissolve triethylamine in organic solvent DMF; Prepare reaction solution C: dissolve methylboric acid in dilute sulfuric acid and organic solvent DMF; n-heptane is the reaction liquid D; The reaction liquid A and the reaction liquid B are respectively transported to the micro mixer I at a set flow rate for mixing, and the mixed materials are transported to the tubular reactor I for the first step reaction to obtain the first step reaction liquid; Reaction liquid C and reaction liquid D are respectively transported to the micro mixer II with the first step reaction liquid at a set flow rate for mixing, and the mixed materials are transported to the tubular reactor II for the second step reaction to obtain the second step reaction liquid; The flow rates of reaction liquid A, reaction liquid B, reaction liquid C and reaction liquid D were all 2.5 mL / min; the reaction temperatures were all room temperature; the residence time of tubular reactor I in the first step reaction was 10 min, and the residence time of tubular reactor II in the second step reaction was 20 min.
